E
Eliane Gluckman
Researcher at University of Paris
Publications - 694
Citations - 48573
Eliane Gluckman is an academic researcher from University of Paris. The author has contributed to research in topics: Transplantation & Bone marrow. The author has an hindex of 112, co-authored 679 publications receiving 46415 citations. Previous affiliations of Eliane Gluckman include Medical College of Wisconsin & Leiden University.
Papers
More filters
Journal ArticleDOI
Influence of Myeloablative Conditioning Regimens on Outcomes after Single Unrelated Cord Blood Transplantation for Adults with Leukemia: An Analysis on Behalf of Eurocord-EBMT-Netcord
Samir Kanaan Nabhan,Vanderson Rocha,William Arcese,Anne Sirvent,Irina Ionescu,Renata Bizzetto,Karim Boudjedir,Wagnara Chaves,Andrée-Laure Herr,Eliane Gluckman,Guillermo Sanz +10 more
TL;DR: Findings support the use of fludarabine based MAC as a strategy to improve neutrophil recovery after single UCBT in patients with unrelated cord blood transplantation and the impact of MAC in this setting is unknown.
Journal ArticleDOI
Unrelated cord blood transplantation for childhood acute myelogenous leukemia: The influence of cytogenetic risk group stratification.
Gérard Michel,Renato Cunha,Annalisa Ruggeri,Tracey A. O'Brien,Henrique Bittencourt,J.-H. Dalle,Francesco Locatelli,A. P. Iori,Marcos Augusto Mauad,Claire Oudin,Federica Giannotti,Fernanda Volt,Eliane Gluckman,Peter Bader,Vanderson Rocha +14 more
TL;DR: Unrelated cord blood transplantation for childhood acute myelogenous leukemia: The influence of cytogenetic risk group stratification is studied.
Journal ArticleDOI
Umbilical cord blood transfusions in low-income countries
TL;DR: A prospective clinical trial set in Kenya, in which red blood cells from umbilical cord blood were used for transfusions in children with severe anaemia, indicates the safety and effi cacy of this innovative approach.
Journal ArticleDOI
Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party.
Mohamad Sobh,Mauricette Michallet,Valérie Dubois,Simona Iacobelli,Linda Koster,Anja van Biezen,Nathalie Fegueux,Reza Tabrizi,Jürgen Finke,Jean El-Cheikh,Martin R. Schipperus,Ellen Meijer,Peter A. von dem Borne,Eefke Petersen,Nigel H. Russell,Eleni Tholouli,Jakob Passweg,Frédéric Garban,Johan Maertens,Patrice Chevalier,Natacha Maillard,Liisa Volin,Sylvie François,Bruno Lioure,Yves Beguin,Eliane Gluckman,Annalisa Ruggeri,Laurent Garderet,Nicolaus Kröger +28 more
TL;DR: Patients may benefit most from the potentially curative effect of graft versus myeloma effect of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and its effects.